#1a 00 HEALTHCARE CELLTRION Nov 2022 Celltrion Healthcare 3Q22 Earnings Presentation#2HEALTHCARE CELLTRION Contents Section 01. 3Q22 Business Results Section 02. Key Business Performance Appendix#3Section 01 3Q22 Business Results HEALTHCARE CELLTRION#43Q22 Business Results Income Statement Revenue Steady growth continued in RemsimaⓇ SC and all other products in Europe & the growth market led sound earnings, partially offset sales reduction in North America OP : Achieved solid operating profit mainly driven by stable prescription & COGS improvement of the high-margin products such as InflectraⓇ and RemsimaⓇ SC NP : Jumped by 238.9% YoY and 251.9% QoQ respectively as a result of the increase in non-operating profit due to weak Won (KRW bn) '21.3Q '22.2Q '22.3Q % YoY %QoQ Revenue 409.1 519.0 496.4 21.3% -4.4% Gross Profit 74.7 140.9 153.1 105.0% 8.7% (%) 18.3% 27.1% 30.8% 12.5%p 3.7%p SG&A 52.7 66.8 80.6 52.9% 20.7% (%) 12.9% 12.9% 16.2% 3.3%p 3.3%p Personnel expenses 12.1 13.7 14.1 16.5% 2.9% Research expenses 5.5 0.8 0.3 -94.5% -62.5% Advertising expenses 3.0 6.6 7.7 156.7% 16.7% Commissions 14.9 24.3 33.1 122.1% 36.2% Operating Profit 22.0 74.1 72.5 229.5% -2.2% (%) 5.4% 14.3% 14.6% 9.2%p 0.3%p EBIT 52.5 95.2 185.2 252.8% 94.5% Net Profit 40.6 39.1 137.6 238.9% 251.9% Investor Relations 2022 4#53Q22 Business Results By Product (Unit: KRW bn) By Region Sales Breakdown (Unit: KRW bn) 519.0 496.4 2% 519.0 496.4 4% 5% 10% 5% LATAM 27% 11% 409.1 409.1 29% 13% -1% 11% Asia 4% 14% 6% 18% 13% 10% 30% 18% 17% 32% 44% 45% 61% 47% 43% 39% 37% 29% '21.3Q RemsimaⓇ / Inflectra '22.2Q TruximaⓇ RemsimaⓇ SC Chemical Note: Others included YuflymaⓇ, Regkirona®, Covid-19 kit and etc. '22.3Q '21.3Q '22.2Q '22.3Q HerzumaⓇ Others Europe N. America Growth market Investor Relations 2022 5#63Q22 Business Results Balance Sheet & Cash Flow Balance Sheet Cash Flow (KRW bn) '21 '22.3Q Change (KRW bn) '21 '22.3Q Cash at beginning of year 231.5 254.9 Total Assets 3,914.7 4,559.0 644.3 Operating -160.2 130.1 Cash and Cash Operating profit 199.4 191.6 254.9 285.0 30.1 Equivalents Working capital -340.2 -42.0 Short Term Others -19.4 -19.5 270.5 213.1 -57.4 Financial Assets Investing -4.2 65.1 Trade and Other 584.1 858.5 274.4 Short term financial assets 28.0 72.8 Receivables Others -32.2 -7.7 Inventories 2,065.7 2,424.0 358.3 Financing 187.8 -165.1 Borrowing and redemption 199.9 -34.6 Total Liabilities 1,808.9 2,364.1 555.2 Share buyback -11.6 -91.0 Cash Dividend -39.9 Total Equity 2,105.8 2,194.9 89.1 Share issue 3.0 3.5 Others -3.5 -3.1 Debt-to-Equity Ratio 85.9% 107.7% 21.8%p Cash at the end of year 254.9 285.0 Investor Relations 2022 6#7Section 02 Key Business Performance HEALTHCARE CELLTRION#8Key Business Performance RemsimaⓇ & InflectraⓇ As the most prescribed Infliximab drug, RemsimaⓇ has steady market share uptake after launching RemsimaⓇ SC in Europe & continuously expanding prescription in Japan & LATAM ✓ In the US, the market share uptake continued by accelerating prescription after additional listings at major US payers M/S of RemsimaⓇ in Europe and Japan M/S of InflectraⓇ in the US 46% 60% 59% 57% 56% 55% 54% 52% 53% 53% 52% 20% 20% 21% 18% 14% 11% 9% 8% 7% 6% 4% 17.2Q 4Q 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 21.2Q 4Q 22.2Q Europe Note: The market share is based on volume Source: IQVIA Japan 23% 32% 12% 9% 9% 8% 6% 7% 6% 4% 3% 1% 0% '18 '19 '20 Inflectra® Note: The market share is based on volume Source: Symphony Health A Biosimilar '21 '22.09 B Biosimilar Investor Relations 2022 8#9Key Business Performance RemsimaⓇ SC ✓ RemsimaⓇ SC prescription has been expanding since its launch in 2020 and driving the growth of Infliximab market in Europe ✓ Switching from InflectraⓇ to RemsimaⓇ led to the increase of prescription of Remsima® SC M/S Trend of CTHC's Infliximab products in Europe M/S of Infliximab products in Europe (as of 2Q22) 33% 33% 33% 32% 30% 29% 37% 35% 35% 34% 25% 25% 24% 24% 24% 25% 20% 19% 17% 15% 12% 9% 8% 5% 3% 3% 2% 90 1% 0% 0% 90 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q RemsimaⓇ RemsimaⓇ SC Note: The market share is based on volume of EU regions RemsimaⓇ SC launched Source: IQVIA InflectraⓇ 13% 15% EU5 66% 34% 38% 7% 15% ex-EU5 53% 47% 31% ■Remicade® + Others RemsimaⓇ InflectraⓇ RemsimaⓇ SC Note: The market share is based on volume Source: IQVIA Investor Relations 2022 9#10Key Business Performance ✓ Real-world RemsimaⓇ SC switching data has been presented at UEGW 2022 RemsimaⓇ SC ✓ Infliximab levels significantly increased post switch to RemsimaⓇ SC at 3m & remained high to 12m ✓ According to the survey, 77% of patients preferred using RemsimaⓇ SC over Infliximab IV Infliximab PK levels of RemsimaⓇ SC switching patients Serum infliximab levels, μg/dl 20 10 H H Baseline 3m 6m 12m Patient satisfaction survey after switching to RemsimaⓇ SC Strongly Disagree (6%) Disagree (6%) Neutral (11%) Strongly Agree (53%) Agree (24%) Source: Philip J Smith et al Efficacy and Safety of Elective Switching From Intravenous to Subcutaneous Infliximab (Ct-P13): A Multi-Centre Cohort Study, Journal of Crohn's and Colitis, 2022;, jjac053, https://doi.org/10.1093/ecco-jcc/jjac053 Investor Relations 2022 10#11Key Business Performance TruximaⓇ In Europe, the market share has decreased during the transition to go direct in 1H22, expected to be recovered gradually with the start of direct sales in 2H22 ✓ Despite pricing pressure amid intensified competition, maintaining stable market share in the US M/S of TruximaⓇ in Europe M/S of TruximaⓇ in the US 18% 39% 40% 35% 38% 37% 36% 31% Volume 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q 3Q TruximaⓇ D Biosimilar Value 29% 24% 17.4Q 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 21.2Q 4Q 22.2Q 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q 3Q MabtheraⓇ Truxima a® C Biosimilar TruximaⓇ D Biosimilar Note: The market share is based on volume Source: IQVIA Source Symphony Health Investor Relations 2022 11 37% 28% 32% 28%#12Key Business Performance ✓ Herzuma®, a leading trastuzumab biosimilar in Europe, started to go direct in 2H22 HerzumaⓇ ✓ Surpassed the market share of HerceptinⓇ in Japan & Increasing demands in LATAM boosted the sales growth M/S of HerzumaⓇ in Europe 1% 10% M/S of HerzumaⓇ in Japan 19% 16% 15% 15% 14% 14% 13% 25% 19.08 approval of 3-weekly regimen 2% 0% 12% 50% 51% 53% 54% 55% 46% 44% 39% 35% 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 21.2Q 4Q 22.2Q 19.2Q 3Q 4Q 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q Herzuma® HerceptinⓇ E Biosimilar F Biosimilar G Biosimilar Note: The market share is based on volume Source: IQVIA HerzumaⓇ Note: The market share is based on volume Source: IQVIA HerceptinⓇ Investor Relations 2022 12#13Key Business Performance YuflymaⓇ ✓ Yuflyma®, a biosimilar with HumiraⓇ's most similar specification, will be launched in the US in Jul.2023 ✓ Initiated a global Phase 3 clinical trial to demonstrate the interchangeability of YuflymaⓇ with HumiraⓇ Global market size of Adalimumab Specifications by product 100% 3% 5%0 Product Name High concentration Interchangeability 5% 15% HumiraⓇ O 75% 16% YuflymaⓇ O Global 13% 80% Adalimumab 50% 19% A X Market Size $34.6bn 7% B Δ 25% 42% 0% ■ HumiraⓇ US ■ Europe ■ROW ImraldiⓇ ■ Hulio® ■ AmgevitaⓇ HyrimozⓇ Idacio® Note: The market size is as of 2021 Source: IQVIA C о D X Note: indicates clinical trial to support interchangeability ongoing Investor Relations 2022 13#14Appendix HEALTHCARE CELLTRION#15Launching Timeline by Product Europe US Europe US Remsima Infliximab INFLECTRA JAFL X MAS Truxima Rituximab Herzuma Trastuzumab 2013 2016 2017 2018 INFLECTRA INFLIXIMAB Vegzelma bevacizumab 2022 2023(E) Vegzelma Yuflyma Note: 1) The logo of Inflectra™ is owned by Pfizer 2) Launching plan could be subjective to the approval bevacizumab adalimumab Regkirona regdanvimab Remsima Infliximab SUBCUTANEOUS Yuflyma adalimumab 2019 2020 2021 Truxima Herzuma® Rituximab Trastuzumab CT-P43 CT-P39 CT-P41 CT-P42 CT-P47 bStelara bXolair bProlia bEylea bActemra 2024(E) 2025(E) 2026(E) Remsima CT-P41 CT-P39 CT-P47 Infliximab SUBCUTANEOUS bProlia bXolair bActemra CT-P43 CT-42 bStelara bEylea Investor Relations 2022 15#16Pipeline Product Name Reference Drug Manufacturer Global Market size ($bn) RemsimaⓇ SC US Celltrion 52.9 In phase 3 clinical trial EU Received EMA approval (Jul.2020, Pediatric usage non-included) Received EMA approval (Feb.2021) Application submitted (Nov.2020) YuflymaⓇ HumiraⓇ (Adalimumab) AbbVie 34.6 In phase 3 clinical trial to support interchangeability Received EMA approval (Aug.2022) VegzelmaⓇ Avastin® (Bevacizumab) Roche 6.1 Received FDA approval (Sep.2022) CT-P43 StelaraⓇ (Ustekinumab) Johnson & Johnson 14.1 In phase 3 clinical trial CT-P39 XolairⓇ (Omalizumab) Genentech 3.7 In phase 3 clinical trial CT-P42 EyleaⓇ (Aflibercept) Bayer & 4.8 In phase 3 clinical trial Regeneron ProliaⓇ CT-P41 Amgen 5.8 In phase 3 clinical trial (Denosumab) CT-P47 Actemra® (Tocilizumab) Roche 3.6 In phase 3 clinical trial Note: Global market size is as of 2021 Source: IQVIA Investor Relations 2022 16#17Summary Income Statement (KRW bn) 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 '19 '20 '21 Revenue 356.9 420.3 463.4 387.0 356.3 433.3 409.1 605.8 415.7 519.0 496.4 1,100.9 1,627.6 1,804.5 Cost of Sales 262.4 292.0 289.4 242.0 274.0 306.1 334.4 459.5 311.4 378.1 343.3 891.6 1,085.8 1,374.0 Gross Profit 94.5 128.3 174.0 145.0 82.3 127.1 74.7 146.4 104.3 140.9 153.1 209.3 541.8 430.5 SG&A 38.7 41.4 46.3 53.3 50.8 50.9 52.7 76.7 59.2 66.8 80.6 126.5 179.7 231.1 Operating Income 55.8 86.8 127.7 91.8 31.5 76.2 22.0 69.7 45.0 (Loss) 74.1 72.5 82.8 362.1 199.4 Non-operating Income 42.4 (18.1) (7.0) (64.5) 3.6 11.8 30.5 (45.9) 16.5 21.2 112.9 (6.7) (47.2) 0.0 Financial Income 22.8 3.6 3.1 9.2 5.5 4.6 2.2 0.8 4.3 3.4 22.8 20.0 38.7 13.1 Financial Expenses 7.4 16.9 8.2 1.4 12.5 3.5 18.5 (2.8) 5.0 13.9 17.2 29.5 33.9 31.7 Other Income 32.5 11.7 7.4 (13.2) 27.0 15.6 51.8 (22.6) 30.9 38.8 114.0 20.8 38.4 71.8 Other Expenses 5.5 16.5 9.3 59.1 16.4 4.9 5.0 26.9 13.7 7.1 6.7 18.0 90.4 53.2 Profit before Taxes 98.2 68.7 120.6 27.2 35.0 87.8 52.5 23.0 61.3 95.2 185.2 75.4 314.7 198.3 Tax Expense (Benefit) 22.0 22.2 34.5 (4.4) 3.5 24.1 11.9 (85.2) 17.7 56.1 47.5 10.4 74.3 (45.7) Net Profit 76.2 46.4 86.1 31.7 31.5 63.7 40.6 16.8 43.6 39.1 137.6 65.0 240.4 152.6 Investor Relations 2022 17#18Thank You HEALTHCARE CELLTRION